Upon binding to PD-L1, which is frequently expressed on cancer cells and antigen-presenting cells, the PD-1/PD-L1 interaction reduces T cell activation, proliferation, and survival leading to T cell exhaustion and protecting cancer cells from destruction mediated by cytolytic T cells (3, 4). Here, PDCD1 is linked to cancer.